4-O-methyl-phorbol-12,13-didecanoate (PMA) is a potent tumor promoter, a member of the phorbol ester family. It is commonly used in research to activate protein kinase C (PKC), a key signaling enzyme involved in cell growth and differentiation. PMA's effects are attributed to its ability to bind to and activate PKC, leading to a cascade of downstream events, including the activation of transcription factors and the production of inflammatory mediators. PMA is synthesized from phorbol, a diterpene compound extracted from the plant Croton tiglium. Its synthesis involves multiple steps, including esterification and methylation reactions. The potent biological activity of PMA, its ability to activate PKC, and its role in tumor promotion make it a valuable tool for studying signal transduction pathways and the development of cancer. PMA is also used as a research tool to study the role of PKC in various cellular processes, including inflammation, immune responses, and apoptosis. Due to its potent activity and its ability to mimic the effects of tumor promoters, PMA is widely used in research to study the molecular mechanisms of cancer development.'
ID Source | ID |
---|---|
PubMed CID | 119493 |
MeSH ID | M0071960 |
Synonym |
---|
54870-24-5 |
4-o-mepdd |
4-o-methyl-phorbol-12,13-didecanoate |
5h-cyclopropa(3,4)benz(1,2-e)azulen-5-one, 1,1a-alpha,1b-beta,4,4a,7a-alpha,7b,8,9,9a-decahydro-7b-alpha,9-beta,9a-alpha-trihydroxy-3-hydroxymethyl-1,1,6,8-alpha-tetramethyl-4a-methoxy-, 9,9a-didecanoate |
decanoic acid, 1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-7b-hydroxy-3-(hydroxymethyl)-4a-methoxy-1,1,6,8-tetramethyl-5-oxo-9ah-cyclopropa(3,4)benz(1,2-e)azulene-9,9a-diyl ester, (1ar-(1aalpha,1bbeta,4abeta,7aalpha,7balpha,8alpha,9beta,9aalpha))- |
7b-hydroxy-3-(hydroxymethyl)-4a-methoxy-1,1,6,8-tetramethyl-5-oxo-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-9ah-cyclopropa[3,4]benzo[1,2-e]azulene-9,9a-diyl didecanoate |
DTXSID60970210 |
[(1s,2s,6r,10s,11r,13s,14r,15r)-13-decanoyloxy-1-hydroxy-8-(hydroxymethyl)-6-methoxy-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] decanoate |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |